Laurel Wealth Advisors, Inc. Galectin Therapeutics Inc Transaction History

Laurel Wealth Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$3.61 - $5.0 $59,926 - $83,000	-16,600 Closed	0 $0
Q2 2018 Aug 20, 2018	SELL	$3.16 - $9.16 $15,168 - $43,968	-4,800 Reduced 22.43%	16,600 $105,000
Q1 2018 May 16, 2018	BUY	$3.78 - $5.97 $80,892 - $127,758	21,400 New	21,400 $101,000
Q4 2017 Feb 15, 2018	SELL	$1.54 - $3.34 $24,640 - $53,440	-16,000 Closed	0 $0
Q2 2017 Aug 15, 2017	BUY	N/A	16,000	16,000 $39,000

112

9.93M

3.78M

5.27M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $94.5M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Laurel Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Laurel Wealth Advisors, Inc. with notifications on news.